Vertex Pharmaceuticals (BSP:VRTX34) Short Percentage of Float


BSP:VRTX34 Vertex Pharmaceuticals Inc BSP:VRTX34
87 GF Score
Price R$607.20
GF Value R$614.03
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

BSP:VRTX34 vs REGN, ALNY, RVMD: Short Percentage of Float Comparison

For the Biotechnology subindustry, Vertex Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vertex Pharmaceuticals Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Short Percentage of Float falls into.


BSP:VRTX34
87GF Score
Vertex Pharmaceuticals Inc BSP:VRTX34
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vertex Pharmaceuticals (BSP:VRTX34) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of R$607.20 is trading 1.1% below its estimated GF Value™ of R$614.03. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for BSP:VRTX34:

  • Short Percentage of Float:
  • GF Value™: R$614.03 vs. price of R$607.20 (1.1% below fair value)
  • GF Score™: 87/100 with 4 warning signs

No single metric tells the full story. See the BSP:VRTX34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
87GF Score

Get the complete analysis for BSP:VRTX34

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$607.20
Price
R$614.03
GF Value